Bull World Health Organ. 1960;22(1-2):185-96.
BCG vaccine is commonly assessed for biological activity by its ability to induce tuberculin sensitivity in guinea-pigs. In 1950, the WHO Expert Committee on Biological Standardization advocated using a sensitizing dose of 5 mg of BCG. It is now known, however, that allergy can be produced by much smaller doses. Since the use of such a low dose that an attenuated vaccine would fail to induce allergy might be advantageous for assessing the biological activity, a further investigation of tuberculin allergy in the guinea-pig has recently been undertaken jointly by the BCG Department of the Statens Seruminstitut, Copenhagen, and the former WHO Tuberculosis Research Office, Copenhagen.As a first step in this investigation, the presence and degree of tuberculin allergy were studied in relation to the dose of BCG administered. The results, presented here, showed that in guinea-pigs, unlike in humans, the production of allergy is to a large extent independent of the vaccine dose. On the other hand, the speed of development and the maximum allergy attained are functions of the dose. It is suggested that the speed of allergy development and the median effective dose in guinea-pigs might be used as criteria for assessing the biological activity of new batches of vaccine.
BCG 疫苗通常通过其在豚鼠中诱导结核菌素敏感性的能力来评估其生物活性。1950 年,世界卫生组织生物标准化专家委员会主张使用 5 毫克 BCG 的致敏剂量。然而,现在已知,较小剂量也可以引起过敏。由于使用如此低剂量的减毒疫苗可能无法引起过敏,这对于评估生物活性可能是有利的,因此最近哥本哈根 Statens Seruminstitut 的 BCG 部门和前世界卫生组织结核病研究办公室联合对豚鼠的结核菌素过敏进行了进一步调查。作为该研究的第一步,研究了给予 BCG 剂量与结核菌素过敏的存在和程度的关系。这里提出的结果表明,在豚鼠中,与人类不同,过敏的产生在很大程度上与疫苗剂量无关。另一方面,过敏的发展速度和达到的最大过敏程度是剂量的函数。有人建议,豚鼠过敏发展的速度和中效剂量可以用作评估新批次疫苗生物活性的标准。